Eko Low Ejection Fraction Tool (ELEFT)

by Eko Health  · Based in United States →Your new partner in precise, proactive heart and lung care.
Cardiology Family Medicine Internal Medicine

Contact for pricing
Regulatory Status Disclosed

Overview

The Eko Low Ejection Fraction Tool (ELEFT) is an innovative AI-powered algorithm developed by Eko Health in collaboration with Mayo Clinic. It is designed to aid clinicians in the early identification of individuals with Left Ventricular Ejection Fraction (LVEF) less than or equal to 40%, a key indicator of heart failure.

ELEFT integrates seamlessly with FDA-cleared Eko Digital Stethoscopes, such as the CORE 500™, to analyze both electrocardiogram (ECG) and heart sound (PCG) recordings during a routine physical examination. The software uses advanced signal processing and machine learning algorithms to provide a likelihood of low EF within approximately 15 seconds.

This tool is intended to assist healthcare providers in assessing LVEF ≤ 40% and is not a diagnostic tool on its own, but rather a screening tool to prompt further referral or diagnostic follow-up. By embedding rapid and accessible low ejection fraction detection into a familiar stethoscope exam, ELEFT aims to disrupt the status quo of delayed heart failure diagnoses, which often occur due to the inaccessibility or cost of traditional methods like echocardiography in primary care settings.

ELEFT is a component of Eko’s SENSORA™ Cardiac Early Detection Platform, which also includes FDA-cleared algorithms for detecting AFib and structural heart murmurs.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Key Features

  • AI-powered low ejection fraction detection
  • Integrates with FDA-cleared Eko digital stethoscopes
  • Analyzes ECG and heart sound recordings
  • Provides results in approximately 15 seconds
  • Part of the SENSORAu2122 Cardiac Early Detection Platform
  • Cloud-based data processing and storage
  • Aids in early identification of heart failure risk
  • Non-invasive screening tool

Use Cases

  • Early detection of heart failure with reduced ejection fraction (HFrEF)
  • Screening for low LVEF in primary care settings
  • Aiding clinicians in identifying at-risk patients during routine physical exams
  • Supporting timely referrals for further diagnostic follow-up
  • Enhancing cardiac assessment in telemedicine and remote monitoring (with Eko stethoscopes)

What Physicians Need to Know

ECG/EKG Analysis Capability
The Eko Low Ejection Fraction Tool (ELEFT) analyzes single-lead electrocardiogram (ECG) and heart sound (phonocardiogram - PCG) data collected via Eko digital stethoscopes. It utilizes machine learning algorithms for this analysis.
Echocardiography AI Features
ELEFT is not an echocardiography AI tool. Instead, it is designed to aid clinicians in identifying individuals with Left Ventricular Ejection Fraction (LVEF) less than or equal to 40% by analyzing ECG and heart sounds, particularly in settings where echocardiography is not readily available or indicated. Its performance has been evaluated against echocardiographic EF measurements.
Arrhythmia Detection Accuracy
ELEFT's primary function is LVEF detection and it is not intended to detect arrhythmias. However, studies have shown that among patients flagged by the AI for potential low EF but with normal echocardiograms, a significant percentage had conduction or rhythm abnormalities, suggesting an indirect indication of underlying rhythm issues.
Heart Failure Risk Prediction
ELEFT is intended to aid in identifying individuals with LVEF u2264 40%, a key indicator of heart failure. Patients identified with reduced ejection fraction using Eko Health AI were found to be twice as likely to experience major adverse cardiac events (MACE), including heart attacks, heart failure, hospitalization, and all-cause mortality over two years.
Cardiac Monitoring Integration
ELEFT integrates with FDA-cleared Eko digital stethoscopes (e.g., Eko DUO) to collect ECG and heart sound data. This data is saved as .WAV files in the secure Eko Cloud and can be accessed and displayed on connected mobile devices (smartphones, tablets) or PCs.
AHA/ACC Guideline Alignment
The algorithm uses an LVEF threshold of 40%, which aligns with the point at which most patients become eligible for guideline-directed therapy for heart failure. Early detection of left ventricular dysfunction is emphasized as crucial for improving patient outcomes.
Real-Time Alert Capability
The ELEFT algorithm can provide an actionable signal within approximately 15 seconds when paired with Eko's electronic stethoscopes. It delivers machine learning-based notifications indicating the likelihood of LVEF u2264 40%, prompting further referral or diagnostic follow-up.
Physician Tip

ELEFT serves as a valuable screening tool, particularly in primary care and resource-limited settings, to identify patients at risk for low ejection fraction and potential heart failure earlier. It is crucial to remember that ELEFT is not a standalone diagnostic tool; a positive result necessitates further diagnostic evaluation, such as echocardiography, to confirm the diagnosis and guide treatment. Integrate ELEFT findings with a comprehensive clinical assessment, including patient history and symptoms, for optimal patient management. Early identification can facilitate timely specialist referrals and initiation of guideline-directed therapies, potentially preventing hospitalizations and adverse cardiac events.

ELEFT is integrated into Eko's SENSORAu2122 Cardiac Early Detection Platform, which also features other FDA-cleared algorithms for detecting atrial fibrillation and structural heart murmurs. The system relies on data input from Eko's digital stethoscopes and leverages a cloud-based API for data processing and result display across various devices.

Details

Category Cardiology AI, Clinical Decision Support & Reference
Pricing Contact for pricing
  • ELEFT is part of Eko's SENSORA™ platform, an enterprise solution
  • Contact Eko Health sales for specific pricing
DeploymentCloud-based software integrated with Eko digital stethoscopes.
Compliance
BAA AvailableUnknown AI-estimated
HIPAA CompliantUnknown AI-estimated
FDA Status 1 AI-estimated

Eko Low Ejection Fraction Tool (ELEFT) received FDA 510(k) clearance (K233409) on March 28, 2024. It is classified as Cardiovascular Machine Learning-Based Notification Software, intended to aid clinicians in identifying individuals with Left Ventricular Ejection Fraction (LVEF) less than or equal to 40%.

Integrations
EHR Not specified
Specialties Cardiology, Family Medicine, Internal Medicine

What the Web Says

The Eko Low Ejection Fraction Tool (ELEFT) is an AI-powered software designed to assist clinicians in identifying individuals with a Left Ventricular Ejection Fraction (LVEF) of less than or equal to 40%, a key indicator of heart failure. It analyzes ECG and heart sounds collected via Eko stethoscopes, providing a rapid screening tool during routine physical exams. ELEFT aims to enable earlier detection of heart failure, particularly in primary care settings where traditional diagnostic tools like echocardiography may be less accessible.

Overall: Positive

Strengths

  • Rapid detection of low ejection fraction in approximately 15 seconds.
  • Aids in early identification of heart failure, potentially preventing hospitalizations and adverse events.
  • Utilizes a familiar tool (stethoscope) for screening, making it accessible in various clinical settings, including underserved areas.
  • Developed in collaboration with Mayo Clinic and validated through clinical studies.
  • FDA-cleared and integrated into Eko's Sensora Cardiac Early Detection Platform, which also detects AFib and structural heart murmurs.
  • Demonstrated effectiveness in identifying pregnancy-related cardiomyopathy.

Limitations

  • Not intended as a sole means of diagnosis and should not replace an echocardiogram when indicated.
  • Requires recordings collected by healthcare professionals or operators with at least 5 years of experience in clinical data collection.
  • Performance data, while strong, shows a sensitivity of around 74.7-77.5% and specificity of 77.5-78.3% for LVEF <= 40%.
  • The software itself is an API only, without a user interface, and requires access to a separate software program for output display.
  • The algorithm was validated on a proprietary database.

Based on reviews from: Eko Health, Inc. (accessdata.fda.gov), MobiHealthNews, BioWorld, Eko Health, PR Newswire, Forbes, MedTech Dive, 24x7 Magazine, Fierce Healthcare, Journal of the American College of Cardiology (JACC) Advances, European Heart Journal u2014 Digital Health, The Lancet Digital Health

Last updated: 2026-07-21

Ratings & Reviews

No reviews yet. Be the first to review this tool!

Rate Eko Low Ejection Fraction Tool (ELEFT)

Clinical Value
Ease of Use
Integration
Support & Docs
Value for Money

Press & Coverage

MobiHealthNews
Eko Health's AI-Enabled Cardiac Tool Receives FDA Clearance
Eko Health received FDA 510(k) clearance for its AI-enabled cardiac tool, the Eko Low Ejection Fraction Tool (ELEFT), which can detect low ejection fraction in 15 seconds during routine exams.
2024-04
accessdata.fda.gov
FDA 510(k) Premarket Notification for Eko Low Ejection Fraction Tool (ELEFT)
This regulatory document details the FDA 510(k) clearance for the Eko Low Ejection Fraction Tool (ELEFT), outlining its intended use to aid clinicians in identifying individuals with Left Ventricular Ejection Fraction (LVEF) less than or equal to 40%.
2024-03
Yesil Science
Eko Health Launches CORE 500 Digital Stethoscope in the UK
Eko Health introduced the CORE 500 Digital Stethoscope in the UK, highlighting that in 2024, the company received FDA 510(k) clearance for its Eko Low Ejection Fraction Tool (ELEFT) for early detection of heart failure.
2025-04
Medical Dialogues
FDA clears AI tool to detect heart failure with low ejection fraction
The FDA has cleared the Eko Low Ejection Fraction Tool (ELEFT), an algorithm designed to assist physicians in identifying adults aged 18 and older with a left ventricular ejection fraction of 40% or less.
2024-04
PMC (PubMed Central)
Artificial intelligence guided screening for cardiomyopathies in an obstetric population: a pragmatic randomized clinical trial
This peer-reviewed article references the Eko Low Ejection Fraction Tool (ELEFT) in the context of AI-enabled electrocardiograms for identifying cardiovascular pathologies, including low left ventricular ejection fraction.
2024-09
MDPI
Machine Learning-Enabled Medical Devices Authorized by the US Food and Drug Administration in 2024: Regulatory Characteristics, Predicate Lineage, and Transparency Reporting
This peer-reviewed publication lists the Eko Low Ejection Fraction Tool (ELEFT) as an FDA-authorized machine learning-enabled medical device in 2024, cleared via the 510(k) pathway for low ejection fraction detection from heart sounds.
2025-12
PMC (PubMed Central)
Artificial Intelligence Enabled Prediction of Heart Failure Risk from Single-lead Electrocardiograms
This peer-reviewed article cites the FDA clearance document for the Eko Low Ejection Fraction Tool (ELEFT) in its discussion of AI-ECG models for identifying left ventricular systolic dysfunction and predicting new-onset heart failure.
2024-05
PMC (PubMed Central)
Artificial Intelligence Tools for Preconception Cardiomyopathy Screening Among Women of Reproductive Age
This peer-reviewed study mentions the Eko Low Ejection Fraction Tool (ELEFT) in the context of AI-ECG and AI-stethoscope models for detecting left ventricular systolic dysfunction in women of reproductive age.
2024-03

Videos

Product demos, reviews, and walkthroughs for Eko Low Ejection Fraction Tool (ELEFT).

View all on YouTube

Frequently Asked Questions

ELEFT integrates into routine physical exams using an Eko stethoscope, providing a low ejection fraction detection in approximately 15 seconds. It is intended to aid clinicians in identifying individuals with Left Ventricular Ejection Fraction (LVEF) less than or equal to 40%, particularly in patients at risk for heart failure due to conditions like coronary artery disease, diabetes mellitus, cardiomyopathy, hypertension, and obesity.
ELEFT received FDA 510(k) clearance in April 2024 as an AI-enabled cardiac tool for early detection of low ejection fraction. Eko ensures data privacy and HIPAA compliance through industry-recommended policies, 256-bit AES encryption, nightly backups, Business Associate Agreements (BAA) with subcontractors, and SOC 2 certification for secure facilities.
ELEFT is a screening tool designed to quickly identify potential low ejection fraction at the point of care, where traditional methods like echocardiography are often unavailable due to cost, specialized training, and time constraints. While echocardiography remains the gold standard for diagnosis, ELEFT has demonstrated strong predictive performance, with an AUROC of 0.835, 74.7% sensitivity, and 77.5% specificity for detecting LVEF <40% in clinical validation.
While specific pricing tiers for practices are not detailed, the Centers for Medicare & Medicaid Services (CMS) established a $128.90 payment rate per use for Eko Health's Sensora platform, which includes ELEFT, as of July 2025. The American Medical Association (AMA) has also issued a Category III CPT code for Eko's AI disease detection algorithms, providing a pathway for documentation and potential reimbursement.
ELEFT is intended as a decision support tool to aid clinicians and should not be used as the sole means of diagnosis or to replace an echocardiogram when indicated. It is not designed to monitor disease progression or detect heart attacks. Factors such as poor ECG quality can lead to data exclusions, and the device is intended for use by healthcare professionals or operators with at least five years of experience in clinical data collection.
ELEFT has been clinically validated in a multi-site, prospective study involving 3,456 patients, demonstrating an AUROC of 0.835 for LVEF <40%, with 74.7% sensitivity and 77.5% specificity. An independent validation by Imperial College London also reported an AUROC of 0.85, 84.8% sensitivity, and 69.5% specificity in real-world settings, leading to expanded deployment in UK clinics.

Related Tools

Cardiomatics
Cardiomatics
Cardiology AI
Cardiomatics is a cloud-based, AI-powered software for analyzing ambulatory (Holter) ECG tests, using clinically validated algorithms to provide accurate and high-quality results for cardiac diagnostics. It aims to streamline ECG analysis, reduce interpretation time, and improve diagnostic accuracy for various heart conditions.
SafeBeat Rx App
SafeBeat Rx, Inc.
Cardiology AI
An AI application designed to support safe pharmacological treatment and monitoring for cardiac arrhythmias.
PreemptiveAI Clinical SDK
Measure Labs, Inc. (Dba Preemptiveai, Inc.)
Cardiology AI
A clinical software development kit using AI to model and predict cardiovascular health metrics, aiming to shift healthcare from reactive to proactive by providing early health risk signals.
Clarius Ejection Fraction AI
Clarius Mobile Health Corp.
Cardiology AI
Clarius Ejection Fraction AI is an AI-powered ultrasound tool for automated left ventricular ejection fraction calculation, integrated into the Clarius Ultrasound App for real-time cardiac assessments.
Automated Aortic Stenosis Software (AutoAS)
Multiple companies are developing Automated Aortic Stenosis Software (AutoAS) or similar AI-powered solutions. Notable ones include iCardio.ai, Us2.ai, AccurKardia, HeartSciences Inc., and Echo IQ.
Cardiology AI
Automated Aortic Stenosis Software (AutoAS) is an ultrasound application by GE Medical Systems that provides automated assessment of aortic stenosis to enhance diagnostic efficiency and consistency.
ECG-AI Pulmonary Hypertension (PH) 12-Lead algorithm
Anumana
Cardiology AI
An AI algorithm that analyzes standard 12-lead ECG recordings to detect signs of pulmonary hypertension, aiming for earlier diagnosis and improved patient outcomes.

See all Cardiology AI tools →

More from Eko Health

Eko Foundation Analysis Software with Transformers (EFAST)
Eko Health
Cardiology AI
EFAST by Eko Health is an advanced, FDA-cleared AI model that assists clinicians in identifying structural murmurs associated with heart disease and detecting atrial fibrillation, providing real-time, actionable cardiac insights during routine exams.

View company profile →

Suggest an Edit → | Last Verified: 2026-04-20 | First Added: 2026-04-20

Investors who backed Eko Low Ejection Fraction Tool (ELEFT)

Funded through the company that built this tool.

Tomorrow Capital
VC T2
Mumbai, India
$1M-$5M
Tomorrow Capital is a Mumbai-based early-stage operational VC with a clear focus on tech-enabled healthcare delivery and consumer wellness brands, writing checks…
Care Delivery / Tech-Enabled Services Wellness / Consumer Health
Lightbox Ventures
VC T2
Mumbai, India
$5M-$25M
Lightbox Ventures is a Mumbai-based venture capital firm with a multi-vintage record of backing consumer technology and wellness platforms in India. Check…
Digital Health Wellness / Consumer Health
EDBI
Corporate VC AI T2
Singapore, Singapore
$5M-$25M
EDBI is the strategic investment arm of the Singapore Economic Development Board, headquartered in Singapore with a global mandate and a long…
AI/ML in Healthcare Biotech
Pegasus Capital
PE T3
Dublin, Ireland
$5M-$25M
Pegasus Capital is a Dublin-based corporate finance and private equity advisory firm that executes high-value domestic health sector transactions across Ireland. The…
Care Delivery / Tech-Enabled Services
Sutter Health Ventures
Corporate VC T3
Sacramento, United States
$1M-$5M
Sutter Health Ventures is the strategic venture entity of Sutter Health, a major California-based health system headquartered in Sacramento. The fund backs…
Care Delivery / Tech-Enabled Services Digital Health
ah! Ventures
Angel Network T3
Mumbai, India
<$250k
ah! Ventures is one of India’s earliest organized angel networks and a multi-stage early-stage investor backing founders across consumer, fintech, SaaS, healthcare,…
Digital Health MedTech
Wildwood Ventures
VC T3
Denver, United States
$250k-$1M
Wildwood Ventures, at wildwood.vc with LinkedIn and Crunchbase profiles, is an early-stage venture firm without disclosed stage, sector, or check size in…
AI/ML in Healthcare Digital Health
Ulu Ventures
VC T3
Palo Alto, United States
$1M-$5M
Ulu Ventures is a Bay Area early-stage firm at uluventures.com with a Crunchbase profile and active LinkedIn presence, known for a disciplined…
AI/ML in Healthcare Care Delivery / Tech-Enabled Services
Target Global
VC T3
Berlin, Germany
$1M-$5M
Target Global is a European multi-stage technology investment firm with offices in Berlin, London, and other locations, investing across software, marketplaces, financial…
AI/ML in Healthcare Care Delivery / Tech-Enabled Services
Lifeforce Capital
VC T3
San Francisco, United States
$250k-$1M
Lifeforce Capital presents as an early-stage venture investor with a thesis tilt toward longevity, performance health, and consumer biology, though detailed public…
AI/ML in Healthcare Biotech
Keiretsu Forum Spain
Angel Network T3
Barcelona, Spain
$250k-$1M
Keiretsu Forum Spain is the Spanish chapter of the global Keiretsu Forum angel investment network, comprised of accredited angel investors who collectively…
Biotech Diagnostics
AI Tool Finder
AI-powered search. Results may not be comprehensive.